Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PTI-6D2 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| PTI-6D2 | DRUG | monoclonal antibody |
Inclusion Criteria: * Patients must have histologically or clinically confirmed malignant melanoma of one of the following stages (according to 2002 American Joint Committee on Cancer criteria: Appendix C): Unresectable Stage III disease or Stage IV disease * Patients must have measurable disease a...
Top 20 of 51 competitors
PTI-6D2 is an investigational small molecule being studied for the treatment of metastatic melanoma. It is a radiopharmaceutical agent that has been evaluated in a Phase 1 clinical trial. The drug is not approved and remains in clinical development.
PTI-6D2 is a radiopharmaceutical that delivers a radioactive isotope, rhenium-188, to cancer cells. It is designed to target and bind to melanoma cells, allowing for targeted radiation therapy. The specific molecular target has not been disclosed.
PTI-6D2 is being developed by Cassava Sciences, Inc., a biopharmaceutical company. The company conducted a Phase 1 clinical trial of the drug in patients with metastatic melanoma. Cassava Sciences is publicly traded under the ticker symbol FLNA.
PTI-6D2 is in Phase 1 clinical development. A Phase 1 dose escalation and safety study has been completed. The drug is investigational and has not received regulatory approval for any use.
PTI-6D2 has been studied in one clinical trial, NCT00734188, titled "Dose Escalation and Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma." This Phase 1 trial enrolled 21 participants in Israel and has been completed.
Yes, PTI-6D2 is also known as 188Re-PTI-6D2, which refers to the drug labeled with the radioactive isotope rhenium-188. The clinical trial NCT00734188 used this name to describe the investigational agent.